Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation



    LOS ANGELES, CA, June 18 /CNW/ - Canopus BioPharma, Inc. (OTC: CBIA), a
biotechnology company developing pharmaceutical products and assay methods for
patients suffering from infectious disease, radiation sickness, cancer and
addiction, today announced the signing of a licensing agreement with the
Wisconsin Alumni Research Foundation (WARF), an organization serving the
University of Wisconsin-Madison scientific community by patenting the
discoveries of UW-Madison researchers and licensing these technologies to
leading companies in Wisconsin, the United States and worldwide. The agreement
provides comprehensive licensing rights and patent protection relating to
Canopus' Phase II oncology drug candidate, CB1400.
    "Securing the rights to the WARF patents strengthens Canopus BioPharma's
intellectual property position for future licensing opportunities of CB1400,
one of our most exciting products," said Patrick Prendergast, Chairman and
Chief Executive Officer of Canopus BioPharma. "In the near future, we expect
to announce important results from our studies using CB1400, which will
further validate the potential significance of our drug for oncology and
related indications."
    Canopus BioPharma expects to develop CB1400 as a method for preventing
and reducing mucositis (lesions in the gastrointestinal and oral mucosa caused
by chemo- and/or radiotherapy). The domestic market alone for a preventative
anti-mucositis agent is estimated to be over $1 billion per annum. The
compound underlying CB1400 had been previously developed and patented by a
major pharmaceutical company as an anti-parasitic agent. Canopus discovered
that this approved drug was highly effective for an alternative indication,
specifically for use in preventing mucositis. Canopus BioPharma's market
opportunity with CB1400 includes various applications associated with cancer
therapy and cancer treatment side effects.
    CB1400, a former anti-schistosomal drug, is currently in phase II
clinical development by Canopus as an anti-mucositis preventative agent in
patients receiving radio- and/or chemotherapy treatment. CB1400 alone and in
combination with both cisplatin and cetuximab (Erbitux), has also been shown
to inhibit tumor growth in two mice models of lung cancer, thus demonstrating
the broad capabilities of this compound in the treatment of cancer.

    About the Wisconsin Alumni Research Foundation:

    The Wisconsin Alumni Research Foundation (WARF) supports research at the
University of Wisconsin-Madison by protecting the intellectual property of
University faculty, staff and students, and licensing inventions resulting
from their work. Through these efforts, university ideas benefit the public by
bringing resources back to the university to continue the cycle of investment,
research and invention. WARF (www.warf.org) was established in 1925 as the
first university-based technology transfer office in the world.

    About Canopus BioPharma, Inc.:

    Canopus BioPharma, Inc. (OTC: CBIA) is dedicated to providing the safest,
most cost effective and efficacious pharmaceutical products and assay methods
in the areas of infectious disease, radiation protection, cancer, and
addiction. With innovative science, proven research and development
leadership, and superior products and compounds, Canopus BioPharma has, since
2001, been committed to becoming a market trend setter in a new era of
healthcare. In addition, the Company is a world leader in the development of
novel camelid antibody products to provide unique avenues of progress and
improvement in assay methods and monitoring capabilities for physicians,
patients and researchers, initially for food chain protection applications.
Canopus maintains staff in Australia, South Africa, Ireland, Panama and the
USA. Additional information on the Company is available at
http://www.canopusbiopharma.com.





For further information:

For further information: Len Rothstein, President, Tel: (818) 980-5008,
Fax: (818) 980-5088, len@canopusbiopharma.com

Organization Profile

CANOPUS BIOPHARMA, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890